Biotrofix's mission is to provide the highest-quality preclinical efficacy contract services for CNS, vascular and other diseases to our Clients, who include biotech and pharmaceutical companies, as well as academic investigators.
Special strengths include extensive experience and expertise in preclinical modeling of CNS and vascular diseases, as well as a thorough understanding of all aspects of the drug development pathway.
Biotrofix possesses special expertise in small animal surgery, drug delivery methods, and behavioral assessment methods.
The goal is to provide high-level technical proficiency to Clients, as well as expert assistance in the planning, analysis and interpretation of preclinical efficacy studies. We're open, collaborative, and flexible regarding Clients' needs.
Biotrofix, Inc. was founded by Dr. Seth P. Finklestein and Dr. JingMei Ren, who have over 25 and 15 years of experience, respectively, in this field, in both academic and industrial settings.
Biotrofix is located in well-equipped laboratories, with an AAALAC-accredited animal facility. Biotrofix performs its services on a strictly fee-for-service basis, and takes no intellectual property rights on the work it does for clients.
A comprehensive report is submitted to clients at the end of each study. Biotrofix currently provides contract services for several leading biotech and global pharmaceutical companies.